Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NuriPep 1653 is an experimental **antimicrobial peptide** biologic composed of 22 amino acids with the sequence VRGLAPKKSLWPFGGPFKSPFN. It was identified by computational mining from the P54 nutrient reservoir protein of *Pisum sativum* and reported as a non-modified peptide with rapid bactericidal activity against multidrug-resistant and pan-drug resistant *Acinetobacter baumannii*. Preclinical work indicates membrane-active antibacterial effects, low observed propensity to induce resistance, lack of cytotoxicity in tested human cell lines, and in vitro synergy with colistin. Based on the provided evidence, it appears to be a research-stage anti-infective peptide described in the academic literature rather than a clinically advanced or commercially identified development asset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NuriPep 1653.